SG11201809456UA - Interferon beta antibodies and uses thereof - Google Patents
Interferon beta antibodies and uses thereofInfo
- Publication number
- SG11201809456UA SG11201809456UA SG11201809456UA SG11201809456UA SG11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA SG 11201809456U A SG11201809456U A SG 11201809456UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- avenue
- street
- antibodies
- boston
- Prior art date
Links
- 102000003996 Interferon-beta Human genes 0.000 title abstract 3
- 108090000467 Interferon-beta Proteins 0.000 title abstract 3
- 229960001388 interferon-beta Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 241000036313 Cupressus torulosa Species 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662329327P | 2016-04-29 | 2016-04-29 | |
US201662339709P | 2016-05-20 | 2016-05-20 | |
US201762483669P | 2017-04-10 | 2017-04-10 | |
PCT/US2017/030089 WO2017189983A1 (en) | 2016-04-29 | 2017-04-28 | Interferon beta antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809456UA true SG11201809456UA (en) | 2018-11-29 |
Family
ID=59215947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809456UA SG11201809456UA (en) | 2016-04-29 | 2017-04-28 | Interferon beta antibodies and uses thereof |
Country Status (29)
Country | Link |
---|---|
US (3) | US10829553B2 (ar) |
EP (2) | EP4273165A3 (ar) |
JP (2) | JP6799076B2 (ar) |
KR (1) | KR102527840B1 (ar) |
CN (1) | CN109069606B (ar) |
AU (1) | AU2017258492B2 (ar) |
BR (1) | BR112018072118A2 (ar) |
CA (1) | CA2965652A1 (ar) |
CO (1) | CO2018012497A2 (ar) |
DK (1) | DK3448419T5 (ar) |
ES (1) | ES2950288T3 (ar) |
FI (1) | FI3448419T3 (ar) |
HR (1) | HRP20230605T1 (ar) |
HU (1) | HUE063621T2 (ar) |
IL (1) | IL262244B2 (ar) |
MX (1) | MX2018013222A (ar) |
MY (1) | MY194084A (ar) |
NZ (1) | NZ747225A (ar) |
PE (1) | PE20190371A1 (ar) |
PH (1) | PH12018502275A1 (ar) |
PL (1) | PL3448419T3 (ar) |
PT (1) | PT3448419T (ar) |
RU (1) | RU2750454C2 (ar) |
SA (1) | SA518400327B1 (ar) |
SG (1) | SG11201809456UA (ar) |
SI (1) | SI3448419T1 (ar) |
TW (1) | TWI776808B (ar) |
WO (1) | WO2017189983A1 (ar) |
ZA (1) | ZA201806682B (ar) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018072118A2 (pt) | 2016-04-29 | 2019-03-19 | Pfizer Inc. | anticorpos de interferona beta e usos dos mesmos |
CN109790526A (zh) | 2016-07-01 | 2019-05-21 | 分解治疗有限责任公司 | 优化的二核酸酶融合体和方法 |
KR20200039778A (ko) | 2017-08-22 | 2020-04-16 | 사나바이오, 엘엘씨 | 가용성 인터페론 수용체 및 그의 용도 |
MA52366A (fr) | 2018-04-25 | 2021-03-03 | Prometheus Biosciences Inc | Anticorps anti-tl1a optimisés |
CA3127890A1 (en) * | 2019-01-31 | 2020-08-06 | Immunecent Biotechnology, Inc. | Anti-ifnar1 antibodies |
MX2022004942A (es) | 2019-10-24 | 2022-07-27 | Prometheus Biosciences Inc | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. |
CN114733455B (zh) * | 2022-04-15 | 2023-02-14 | 北京田园奥瑞生物科技有限公司 | 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物精子分型的方法 |
WO2024062420A1 (en) * | 2022-09-22 | 2024-03-28 | Pfizer Inc. | METHODS OF TREATMENT WITH IFNß ANTIBODIES |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
EP0440686B1 (en) * | 1988-10-14 | 1996-01-03 | Berlex Laboratories, Inc. | Peptides representing epitopic sites on r-ifn-beta, antibodies thereto, and uses thereof |
US6682896B1 (en) * | 1988-10-14 | 2004-01-27 | Schering Aktiengesellschaft | Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL108584A (en) | 1994-02-07 | 2008-03-20 | Yeda Res & Dev | Cloning of the interferon-binding protein ALPHA / BETA |
ZA9811070B (en) | 1997-12-08 | 2000-07-03 | Genentech Inc | Type I interferons. |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
WO2004058184A2 (en) | 2002-12-24 | 2004-07-15 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
KR20140021589A (ko) | 2011-04-07 | 2014-02-20 | 제넨테크, 인크. | 항-fgfr4 항체 및 사용 방법 |
CN102898521A (zh) * | 2011-07-26 | 2013-01-30 | 上海市免疫学研究所 | 抗β-干扰素单克隆抗体及其应用 |
US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
CN108348600A (zh) * | 2015-06-26 | 2018-07-31 | 比奥贝拉蒂美国公司 | 治疗自身免疫病症和同种免疫病症的方法 |
BR112018072118A2 (pt) | 2016-04-29 | 2019-03-19 | Pfizer Inc. | anticorpos de interferona beta e usos dos mesmos |
-
2017
- 2017-04-28 BR BR112018072118-2A patent/BR112018072118A2/pt unknown
- 2017-04-28 US US15/581,079 patent/US10829553B2/en active Active
- 2017-04-28 MX MX2018013222A patent/MX2018013222A/es unknown
- 2017-04-28 CA CA2965652A patent/CA2965652A1/en active Pending
- 2017-04-28 DK DK17733171.7T patent/DK3448419T5/da active
- 2017-04-28 PE PE2018002056A patent/PE20190371A1/es unknown
- 2017-04-28 KR KR1020187034153A patent/KR102527840B1/ko active IP Right Grant
- 2017-04-28 JP JP2018556490A patent/JP6799076B2/ja active Active
- 2017-04-28 ES ES17733171T patent/ES2950288T3/es active Active
- 2017-04-28 EP EP23177086.8A patent/EP4273165A3/en active Pending
- 2017-04-28 PL PL17733171.7T patent/PL3448419T3/pl unknown
- 2017-04-28 HU HUE17733171A patent/HUE063621T2/hu unknown
- 2017-04-28 NZ NZ747225A patent/NZ747225A/en unknown
- 2017-04-28 RU RU2018141839A patent/RU2750454C2/ru active
- 2017-04-28 MY MYPI2018703975A patent/MY194084A/en unknown
- 2017-04-28 SG SG11201809456UA patent/SG11201809456UA/en unknown
- 2017-04-28 AU AU2017258492A patent/AU2017258492B2/en active Active
- 2017-04-28 SI SI201731384T patent/SI3448419T1/sl unknown
- 2017-04-28 TW TW106114362A patent/TWI776808B/zh active
- 2017-04-28 CN CN201780025961.XA patent/CN109069606B/zh active Active
- 2017-04-28 WO PCT/US2017/030089 patent/WO2017189983A1/en active Application Filing
- 2017-04-28 FI FIEP17733171.7T patent/FI3448419T3/fi active
- 2017-04-28 IL IL262244A patent/IL262244B2/en unknown
- 2017-04-28 EP EP17733171.7A patent/EP3448419B1/en active Active
- 2017-04-28 HR HRP20230605TT patent/HRP20230605T1/hr unknown
- 2017-04-28 PT PT177331717T patent/PT3448419T/pt unknown
-
2018
- 2018-10-08 ZA ZA2018/06682A patent/ZA201806682B/en unknown
- 2018-10-25 PH PH12018502275A patent/PH12018502275A1/en unknown
- 2018-10-28 SA SA518400327A patent/SA518400327B1/ar unknown
- 2018-11-21 CO CONC2018/0012497A patent/CO2018012497A2/es unknown
-
2020
- 2020-11-09 US US17/092,998 patent/US11858986B2/en active Active
- 2020-11-19 JP JP2020192541A patent/JP7102489B2/ja active Active
-
2023
- 2023-11-16 US US18/511,744 patent/US20240174742A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809456UA (en) | Interferon beta antibodies and uses thereof | |
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201908740VA (en) | Sustained release delivery systems comprising traceless linkers | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201805579SA (en) | Recombinant igg fc multimers | |
SG11201803679TA (en) | Antibodies and antibody fragments for site-specific conjugation | |
SG11201811193TA (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
SG11201809082WA (en) | Nlrp3 modulators | |
SG11201900154VA (en) | Compounds, compositions, and methods for the treatment of disease | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201803676PA (en) | Site specific her2 antibody drug conjugates | |
SG11201408228QA (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
SG11201407548UA (en) | Treatment of amd using aav sflt-1 | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof |